About
Contact
Subscribe
e-Edition

Make Home Page

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook
Twitter

- Site search

Home
News
Sports
- Local Sports
- National Sports
Business
Opinion
A & E
Life
Features & Magazines
- WOMEN
- 2026 Readers' Choice Awards
Classifieds
Weather
Obituaries

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

45.86 -0.46 (-0.99%)

Streaming Delayed Price Updated: 11:09 AM EDT, Aug 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Lumen Tech & Upstart Are Among Top 7 Mid Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio? ↗

August 11, 2024

Lumen, Upstart, ADMA, Sweetgreen, Veracyte, Clear Secure, and Core Scientific were best performers last week. Did you invest in them?

Via Benzinga

Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View ↗

August 07, 2024

Veracyte reports Q2 sales of $114.43M, a 27% increase year over year, surpassing the $100.3 million consensus. Testing revenue rose 31% to $107 million, driven by strong performance of Decipher...

Via Benzinga

Shopify Posts Upbeat Earnings, Joins Axon Enterprise, Aspen Technology, Illumina, Global Payments And Other Big Stocks Moving Higher On Wednesday ↗

August 07, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

August 07, 2024

Pre-market stock movers are a hot topic on Wednesday and we have all of the latest news traders need to know about them this morning!

Via InvestorPlace

A Glimpse Into The Expert Outlook On Veracyte Through 4 Analysts ↗

May 08, 2024

Via Benzinga

Recap: Veracyte Q4 Earnings ↗

February 22, 2024

Via Benzinga

VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q2 2024 ↗

August 06, 2024

VCYT stock results show that Veracyte beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Veracyte Announces Second Quarter 2024 Financial Results

August 06, 2024

From Veracyte, Inc.

Via Business Wire

The 3 Best Personalized Nutrition Stocks to Buy Now ↗

July 24, 2024

Explore personalized nutrition stocks capitalizing on AI, machine learning and genetic profiling to provide targeted dietary solutions.

Via InvestorPlace

Topics Artificial Intelligence

Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024

July 17, 2024

From Veracyte, Inc.

Via Business Wire

Earnings Outlook For Veracyte ↗

February 21, 2024

Via Benzinga

Trading SMID Biotech Stocks In A Volatile Market ↗

July 01, 2024

Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a...

Via Talk Markets

Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness ↗

June 10, 2024

On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). This decision came amidst a period of market fluctuations and followed a...

Via Benzinga

Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors

June 03, 2024

From Veracyte, Inc.

Via Business Wire

Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer

May 22, 2024

From Veracyte, Inc.

Via Business Wire

Veracyte to Participate in Upcoming Investor Conferences

May 15, 2024

From Veracyte, Inc.

Via Business Wire

VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q1 2024 ↗

May 07, 2024

VCYT stock results show that Veracyte beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Veracyte Announces First Quarter 2024 Financial Results

May 07, 2024

From Veracyte, Inc.

Via Business Wire

14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding

May 06, 2024

From Veracyte, Inc.

Via Business Wire

Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024

April 22, 2024

From Veracyte, Inc.

Via Business Wire

New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance

April 22, 2024

From Veracyte, Inc.

Via Business Wire

Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024

April 16, 2024

From Veracyte, Inc.

Via Business Wire

Cathie Wood's Ark Invest Dumps $17M In Coinbase Shares As The Exchange Grappled With Disruption Amid Bitcoin Rally ↗

February 28, 2024

On Wednesday, Cathie Wood-led Ark Invest made a significant move by selling over $17 million worth of Coinbase Global Inc (NASDAQ:COIN) shares.

Via Benzinga

Cathie Wood's Ark Invest Sheds $9.3M Worth Of Coinbase Shares Amid Bitcoin Rally — Robinhood Stock Also Sold ↗

February 27, 2024

On Tuesday, Cathie Wood-led Ark Invest adjusted its portfolio, making significant trades.

Via Benzinga

Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines

February 27, 2024

From Veracyte, Inc.

Via Business Wire

Cathie Wood's Ark Invest Offloads $6.9M Worth of Coinbase, Robinhood Shares Each Amid Searing Bitcoin Rally — Nvidia Stock Also Shed ↗

February 26, 2024

On Monday, Cathie Wood-led Ark Invest adjusted its portfolio, notably selling shares of cryptocurrency-related companies such as Robinhood Markets Inc (NASDAQ:HOOD) and Coinbase Global Inc (NASDAQ:

Via Benzinga

7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff ↗

February 26, 2024

Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off.

Via InvestorPlace

Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results

February 22, 2024

From Veracyte, Inc.

Via Business Wire

Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference

February 21, 2024

From Veracyte, Inc.

Via Business Wire

Earnings Scheduled For February 22, 2024 ↗

February 22, 2024

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Opinion
Photo Galleries
Videos
Local Events
Classifieds
Obituaries

Services

About
Contact
Personnel
Advertise
Subscription Services
Promote Your Event
Dealer Locations
Email Alerts
Submission Forms

Contact Information

chroniclejournal.com
75 S. Cumberland Street
Thunder Bay, ON P7B 1A3
Phone: 807 343 6200
Email: circulation@chroniclejournal.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Veracyte, Inc. - Common Stock (NQ:VCYT)

All News about Veracyte, Inc. - Common Stock

Sections

Services

Contact Information

Follow Us